Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 5 records per page: next > | last >>
pages: 1 2 3 4 5 presentations: 1 to 25 of 103
Introduction
Dr. Ian F. Tannock
Princess Margaret Hospital, Toronto, Ontario, Canada
Peter J. Houghton, Ph.D.
St. Jude Children's Research Hospital, Memphis, TN
from 2005 Annual Meeting on April 16, 2005 9:00 AM-9:05 AM
Taking Molecularly Targeted Agents into Clinical Trial
Julie M. Cherrington, Ph.D.
Phenomix Corporation, San Diego, CA
from 2005 Annual Meeting on April 16, 2005 9:00 AM-9:20 AM
Introduction
Dr. John T. Hunt
Bristol-Myers Squibb Company, Princeton, NJ
from 2005 Annual Meeting on April 16, 2005 9:00 AM-9:05 AM
Pathway-oriented Oncology Target Discovery
Dr. Matt V. Lorenzi
Bristol-Myers Squibb Company, Princeton, NJ
from 2005 Annual Meeting on April 16, 2005 9:05 AM-9:40 AM
Designing Pharmacological Studies and Translational Endpoints for Targeted Agents
Patricia LoRusso, D.O.
Wayne State University, Detroit, MI
from 2005 Annual Meeting on April 16, 2005 9:30 AM-9:50 AM
Learning from Our Mistakes: The Translation of MMPs from Laboratory to Clinical Trial
Barbara M. Fingleton, Ph.D.
Vanderbilt University Medical Center, Nashville, TN
from 2005 Annual Meeting on April 16, 2005 10:00 AM-10:20 AM
Welcome Address: AACR and Its Vital Role in the Prevention and Cure of Cancer
Margaret Foti, Ph.D., M.D. (h.c.), CEO AACR
American Association for Cancer Research, Philadelphia, PA
from 2005 Annual Meeting on April 16, 2005 10:00 AM-10:10 AM
Cancer Research and the Promise for the Eradication of Cancer
Anna D. Barker, Ph.D.
National Cancer Institute, Bethesda, MD
from 2005 Annual Meeting on April 16, 2005 10:10 AM-10:20 AM
The National Cancer Program: New Opportunities for Advancing Progress against Cancer
Andrew C. von Eschenbach, M.D. , Director NCI-NIH
National Cancer Institute, Bethesda, MD
from 2005 Annual Meeting on April 16, 2005 10:20 AM-10:40 AM
ICG-001: A Novel Chemogenomic Tool to Investigate the Wnt Pathway in Cancer
Dr. Michael Kahn
University of Washington, Seattle, WA
from 2005 Annual Meeting on April 16, 2005 10:25 AM-10:50 AM
Model Systems to Help Select Drugs to Be Evaluated in Clinical Trials
Peter J. Houghton, Ph.D.
St. Jude Children's Research Hospital, Memphis, TN
from 2005 Annual Meeting on April 16, 2005 10:30 AM-10:50 AM
How Understanding the Biology of Cancer Can Help You
Lynn M. Matrisian, Ph.D., President of AACR
Vanderbilt University School of Medicine, Nashville, TN
from 2005 Annual Meeting on April 16, 2005 10:40 AM-10:55 AM
The Impact of Cancer Research on Patient Care
James L. Abbruzzese, M.D.
UT M. D. Anderson Cancer Center, Houston, TX
from 2005 Annual Meeting on April 16, 2005 10:55 AM-11:10 AM
The Personal Perspectives of Cancer Survivors
Amy Dilbeck
CureSearch National Childhood Cancer Foundation, Bethesda, MD
from 2005 Annual Meeting on April 16, 2005 11:10 AM-11:30 AM
Introduction
Susan G. Hilsenbeck, Ph.D.
Baylor College of Medicine, Houston, TX
from 2005 Annual Meeting on April 16, 2005 11:15 AM-11:20 AM
Overview of Multiple Approaches to Lead Generation
Dr. Sonya D. Zabludoff
AstraZeneca, Waltham, MA
from 2005 Annual Meeting on April 16, 2005 11:15 AM-11:25 AM
Features of a High Quality Phase I Trial
S. Gail Eckhardt, M.D.
University of Colorado Health Sciences Center, Denver, CO
from 2005 Annual Meeting on April 16, 2005 11:20 AM-11:35 AM
Molecular-targeted Drug Screening at the NCI Center for Cancer Research
Dr. James B. McMahon
National Cancer Institute, Frederick, MD
from 2005 Annual Meeting on April 16, 2005 11:25 AM-11:50 AM
Cancer Prevention: What We Know and What We Need to Do
Thomas A. Sellers, Ph.D.
H. Lee Moffitt Cancer Center & Research Institute
from 2005 Annual Meeting on April 16, 2005 11:30 AM-11:45 AM
Features of a High Quality Phase II Trial
Mace L. Rothenberg, M.D.
Vanderbilt-Ingram Cancer Center, Nashville, TN
from 2005 Annual Meeting on April 16, 2005 11:45 AM-12:05 PM
Statistical Issues in Early Phase Trials
Susan G. Hilsenbeck, Ph.D.
Baylor College of Medicine, Houston, TX
from 2005 Annual Meeting on April 16, 2005 12:15 PM-12:35 PM
Chemical Approaches to Lead Generation
Dr. Martin Pass
AstraZeneca, Macclesfield, United Kingdom
from 2005 Annual Meeting on April 16, 2005 12:25 PM-12:50 PM
Ethical Issues in Early Phase Trials
Dr. Thomas G. Roberts, Jr.
Massachusetts General Hospital, Boston, MA
from 2005 Annual Meeting on April 16, 2005 12:45 PM-1:05 PM
Introduction
Peter Greenwald, M.D., Dr.P.H.
National Cancer Insitute, Bethesda, MD
from 2005 Annual Meeting on April 16, 2005 2:00 PM-2:05 PM
Breast Cancer: Phase III Prevention Trials
Barbara K. Dunn, Ph.D., M.D.
National Cancer Institute, Bethesda, MD
from 2005 Annual Meeting on April 16, 2005 2:00 PM-2:20 PM
<< first | < prev page: of 5 records per page: next > | last >>
pages: 1 2 3 4 5 presentations: 1 to 25 of 103